VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% effective in treating patients with Congenital Sucrase-Isomaltase Deficiency (CSID) when...
Sucraid® (sacrosidase) Oral Solution. Free 4-Day Trial Now Available. The only FDA- approved therapy to treat CSID (Congenital Sucrase-Isomaltase Deficiency)
Seeking Alpha / 4 hours ago 1 Views
Comments